Krsnaa Diagnost.

Q4 FY26

Krsnaa Diagnost. Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹562

Market cap₹1.9K Cr

P/E19.2

Updated23 Aug 2026

Read4 min read

What the Q4 FY26 call signalled

2 of 4 strong

RevenueModerate growth

MarginMargins steady

CapexCapex planned

FundraiseFundraise planned

The short version

Rajasthan project revenue expected between INR 100-150 crores in FY '27, with full installation by Q2 FY '27 and conservative ramp-up assumed. FY '27 expected to see decent scale improvements and at least maintain EBITDA margins, with potential upside from multiple growth levers.

From Krsnaa Diagnost.'s Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Moderate growth

Rajasthan project revenue expected between INR 100-150 crores in FY '27, with full installation by Q2 FY '27 and conservative ramp-up assumed.
Radiology revenue growth anticipated in FY '27, with 10 new MRI centers added in Q1 and 7 more in pipeline, totaling ~260 radiology centers by FY '27 end.
Retail diagnostics is a strong growth driver; retail contribution grew to about 8% in FY '26 and is targeted to scale to 25-30% of total revenue over 3-5 years.
Touchpoints in retail network are growing quarter-on-quarter, with 3,500+ collection points and 500+ franchises nationally.
Organic like-to-like growth on existing PPP projects is around 13% annually.

2 more points management made on revenue & sales performance

Profitability & Margins

FY '27 expected to see decent scale improvements and at least maintain EBITDA margins, with potential upside from multiple growth levers.
Rajasthan project capitalization from Q1 FY '27 with INR 200+ crore capex expected to contribute positively; some initial depreciation and interest costs to impact margins modestly.
Radiology expansion underway with 10 new MRI centers in Q1 FY '27 and total of 17 centers planned, driving future revenue growth.
Retail segment targets contributing 25%-30% of group revenue over 3-5 years, indicating long-term growth focus.
RPL segment expected to move from marginally negative EBITDA in FY '26 to positive EBITDA in FY '27, aiming to reach consolidated EBITDA levels.

2 more points management made on profitability & margins

See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

Rajasthan capital expenditure: Capitalization to happen from Q1 FY '27, around INR 200 crores.
Total INR 500 crores capex planned for FY '27, combining Rajasthan (~INR 300 crores), MRI projects (~INR 150 crores), and smaller projects in Jharkhand and Ranchi.
This INR 500 crores represents capitalization expected in FY '27, involving a mix of debt and internal accruals.
MRI center expansion in Maharashtra includes adding around 10 new MRI centers in the coming quarter (part of a total of 17 centers).
Additional small projects and PPP opportunities under implementation and selective new projects being pursued cautiously.

2 more points management made on capital expenditure plans

Fundraising & Capital Structure

Krsnaa Diagnostics is entering a significant expansion phase which involves capital expenditure of around INR 500 crores in FY '27.
This capex will be funded through a combination of internal accruals and debt.
It is noted that the company has started taking on debt; earlier, Krsnaa had no debt.
Specific details on new fundraising through equity were not mentioned in the provided text.

2 more points management made on fundraising & capital structure

See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Current pipeline includes a couple of PPP projects under implementation, with no major new orders announced yet.
Radiology expansion is ongoing with around 10 MRI centers being added in the current quarter and 7 more planned in coming quarters (total 17).
Expected pathology lab network to reach approximately 297 centers by Q2 FY '27, including Rajasthan additions.
Rajasthan project is under implementation, with major installations expected to complete by Q2 FY '27.
No significant new PPP tender pipelines disclosed for FY '27; growth is expected to be calibrated given current capex and project pipeline.
Board and management are selective about new PPP projects, focusing on long-term value creation rather than aggressive bidding.

2 more points management made on order book & pipeline

Krsnaa Diagnost. — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹173 Cr, net profit ₹43 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Krsnaa Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Gaudium IVF (Q4 FY26)
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25. Key concall takeaways from Gaudium IVF's Q4 FY26 earnings call — and how it ranks…
Apollo Hospitals Enterprise Ltd (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Krsnaa Diagnost. Q4 FY26 results?

What is Krsnaa Diagnost. share price analysis?

Krsnaa Diagnost. currently shows a below-average growth signal. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krsnaa Diagnost. planning capital expenditure?

Rajasthan capital expenditure: Capitalization to happen from Q1 FY '27, around INR 200 crores.

Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.